Diagnosis and treatment of cervical cancer
First Claim
1. A method of diagnosing or aiding in the diagnosis of cervical cancer in a female, comprising analyzing the status of at least two biomarkers selected from the group consisting of:
- hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length, in cervical cells of the female.
3 Assignments
0 Petitions
Accused Products
Abstract
In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.
77 Citations
72 Claims
-
1. A method of diagnosing or aiding in the diagnosis of cervical cancer in a female, comprising analyzing the status of at least two biomarkers selected from the group consisting of:
- hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length, in cervical cells of the female.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
9. A method of diagnosing or aiding in the diagnosis of cervical cancer in a female, comprising analyzing the status of at least two biomarkers, wherein one of the at least two biomarkers is Myc-HPV E6 interaction, and a second biomarker is selected from the group consisting of:
- hTERT, IGFBP-3, transferrin receptor, beta-catenin, HPV E7, and telomere length, in cervical cells of the female.
- View Dependent Claims (10, 11, 12, 13, 14, 15, 16)
-
17. A method of detecting immortalization of cervical cells in a female, comprising analyzing the status of at least two biomarkers selected from the group consisting of:
- hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length, in cervical cells of the female.
- View Dependent Claims (18, 19, 20, 21, 22, 23, 24)
- 25. A method of treating a female suffering from cervical cancer, comprising administering to the female a therapeutically effective amount of an agent which blocks interaction between Myc and HPV E6.
-
30. A method of preventing the onset of cervical cancer or reducing the extent to which it occurs in a female, comprising administering to the female an effective amount of an agent which blocks interaction between Myc and HPV E6, wherein the agent is effective to prevent the onset of cervical cancer or reduce the extent to which it occurs.
- 31. A method of treating a female suffering from cervical cancer, comprising administering to the female a therapeutically effective amount of an agent which blocks or reduces the level of expression of transferrin receptor.
-
37. A method of preventing the onset of cervical cancer or reducing the extent to which it occurs in a female, comprising administering to the female an effective amount of an agent which blocks or reduces the level of expression of transferrin receptor, wherein the agent is effective to prevent the onset of cervical cancer or reduce the extent to which it occurs.
- 38. A method of treating a female suffering from cervical cancer, comprising administering to the female a therapeutically effective amount of an agent which blocks signaling through the beta-catenin pathway.
-
45. A method of preventing the onset of cervical cancer or reducing the extent to which it occurs in a female, comprising administering to the female an effective amount of an agent which blocks signaling through the beta-catenin pathway, wherein the agent is effective to prevent the onset of cervical cancer or reduce the extent to which it occurs.
- 46. A method of treating a female suffering from cervical cancer, comprising administering to the female a therapeutically effective amount of an agent which blocks or reduces the level of expression of hTERT.
-
52. A method of preventing the onset of cervical cancer or reducing the extent to which it occurs in a female, comprising administering to the female an effective amount of an agent which blocks or reduces the level of expression of hTERT, wherein the agent is effective to prevent the onset of cervical cancer or reduce the extent to which it occurs.
- 53. A method of treating a female suffering from cervical cancer, comprising administering to the female a therapeutically effective amount of an agent which blocks or reduces the level of expression of IGFBP-3.
-
59. A method of preventing the onset of cervical cancer or reducing the extent to which it occurs in a female, comprising administering to the female an effective amount of an agent which blocks or reduces the level of expression of IGFBP-3, wherein the agent is effective to prevent the onset of cervical cancer or reduce the extent to which it occurs.
-
60. A method of classifying the grade of a cervical lesion for diagnostic and prognostic purpose in a female, comprising:
-
(a) determining the status of at least two biomarkers in a cervical cell of a female to provide an individual biomarker diagnostic for cervical lesions, wherein the at least two biomarkers are selected from the group consisting of;
hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length;
(b) comparing the status of the at least two biomarkers from (a) with a biomarker reference panel; and
(c) classifying a cervical lesion for the female by said comparison of (b). - View Dependent Claims (61, 62, 63, 64, 65, 66, 67, 68)
-
-
69. A kit for diagnosing or aiding in the diagnosis of cervical cancer, comprising reagents for assessing the status of at least two biomarkers selected from the group consisting of:
- hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length.
- View Dependent Claims (70, 71, 72)
Specification